AU2007235227B2 - Mature dendritic cell compositions and methods for culturing same - Google Patents

Mature dendritic cell compositions and methods for culturing same Download PDF

Info

Publication number
AU2007235227B2
AU2007235227B2 AU2007235227A AU2007235227A AU2007235227B2 AU 2007235227 B2 AU2007235227 B2 AU 2007235227B2 AU 2007235227 A AU2007235227 A AU 2007235227A AU 2007235227 A AU2007235227 A AU 2007235227A AU 2007235227 B2 AU2007235227 B2 AU 2007235227B2
Authority
AU
Australia
Prior art keywords
cells
cd40l
dcs
ifn
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007235227A
Other languages
English (en)
Other versions
AU2007235227A1 (en
Inventor
Melissa Adams
Mark Debenedette
Donald Healey
Atsushi Hinohara
Irina Tcherepanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coimmune Inc
Original Assignee
Coimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coimmune Inc filed Critical Coimmune Inc
Publication of AU2007235227A1 publication Critical patent/AU2007235227A1/en
Assigned to ARGOS THERAPEUTICS, INC., KYOWA HAKKO KIRIN CO., LTD. reassignment ARGOS THERAPEUTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: ARGOS THERAPEUTICS, INC., KIRIN PHARMA KABUSHIKI KAISHA
Application granted granted Critical
Publication of AU2007235227B2 publication Critical patent/AU2007235227B2/en
Assigned to ARGOS THERAPEUTICS, INC. reassignment ARGOS THERAPEUTICS, INC. Request for Assignment Assignors: KYOWA HAKKO KIRIN CO., LTD., ARGOS THERAPEUTICS, INC.
Assigned to COIMMUNE, INC. reassignment COIMMUNE, INC. Request for Assignment Assignors: ARGOS THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4238Regulators of development
    • A61K40/424Apoptosis related proteins, e.g. survivin or livin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4244Enzymes
    • A61K40/4246Telomerase or [telomerase reverse transcriptase [TERT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • A61K40/4272Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56Kidney
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/24Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/52CD40, CD40-ligand (CD154)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2007235227A 2006-04-07 2007-04-06 Mature dendritic cell compositions and methods for culturing same Ceased AU2007235227B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/400,774 US8513008B2 (en) 2004-10-07 2006-04-07 Mature dendritic cell compositions and methods for culturing same
US11/400,774 2006-04-07
PCT/US2007/008734 WO2007117682A2 (en) 2006-04-07 2007-04-06 Mature dendritic cell compositions and methods for culturing same

Publications (2)

Publication Number Publication Date
AU2007235227A1 AU2007235227A1 (en) 2007-10-18
AU2007235227B2 true AU2007235227B2 (en) 2012-10-04

Family

ID=38581685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007235227A Ceased AU2007235227B2 (en) 2006-04-07 2007-04-06 Mature dendritic cell compositions and methods for culturing same

Country Status (10)

Country Link
US (4) US8513008B2 (enExample)
EP (1) EP2003969B1 (enExample)
JP (1) JP5425618B2 (enExample)
KR (1) KR101425686B1 (enExample)
CN (1) CN101460054B (enExample)
AT (1) ATE510451T1 (enExample)
AU (1) AU2007235227B2 (enExample)
CA (1) CA2648675C (enExample)
DK (1) DK2003969T3 (enExample)
WO (1) WO2007117682A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス,インコーポレイティド 樹状細胞組成物および方法
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
WO2009039198A2 (en) * 2007-09-17 2009-03-26 The Trustees Of The University Of Pennsylvania Generation of hyperstable mrnas
BRPI0818736A2 (pt) * 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
CN101969990B (zh) 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
EP2254998B1 (en) * 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CN102971008B (zh) 2010-06-09 2015-11-25 阿肯色大学评议会 降低弯曲菌属感染的疫苗和方法
WO2012041635A1 (en) * 2010-09-29 2012-04-05 Universite De Liege Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
CN109536446B (zh) * 2012-02-10 2022-08-02 医疗法人社团博心厚生会 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
AU2015218865B2 (en) * 2014-02-21 2021-06-10 Coimmune, Inc. TSCM cells and methods for use
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
JP2018535191A (ja) * 2015-09-26 2018-11-29 プライムヴァックス イミュノ−オンコロジー,インク. 樹状細胞を産生するための組成物及び方法
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
WO2017123242A1 (en) * 2016-01-15 2017-07-20 Ding Enyu A universal nucleic acid drug vector enhancing mrna stability and translatability
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー,インク. 癌の処置のための併用免疫療法
CA3049225A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
US11779599B2 (en) 2017-11-07 2023-10-10 Coimmune, Inc. Methods and uses for dendritic cell therapy
CN111166876B (zh) * 2018-11-13 2022-10-11 北京启辰生生物科技有限公司 一种免疫增强剂组合和编码核酸及其应用
KR102698871B1 (ko) * 2021-09-10 2024-08-28 이종균 수지상 세포, 자연 살해 세포 및 세포 독성 t 세포를 포함하는 암의 예방 또는 치료용 생물학적 조성물
WO2024231621A1 (fr) * 2023-05-05 2024-11-14 Centre National De La Recherche Scientifique Acide nucleique synthetique et ses utilisations therapeutiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (en) * 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411228B1 (en) 1989-07-31 1995-11-08 International Business Machines Corporation Controlled fiber-optic switch
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
KR100281264B1 (ko) 1992-10-22 2001-02-01 마나배 게이사꾸 신규한 스핀고당 지질 및 그의 사용
CN1045302C (zh) 1993-04-15 1999-09-29 麒麟麦酒株式会社 新型(神经)鞘糖脂、含有它们的药物组合物及其用途
PL181496B1 (pl) 1996-03-20 2001-07-31 Politechnika Slaska Im Wincent Sposób wytwarzania ß-naftolu PL
AU705647B2 (en) 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
TW555562B (en) 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
ES2235324T3 (es) 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
CA2328604A1 (en) 1998-05-26 1999-12-02 Andrew Segal Compositions and methods of modulating an immune response to an antigen
EP1185627A2 (en) 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US20030077263A1 (en) 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
ES2389645T3 (es) 2000-06-19 2012-10-30 Beth Israel Deaconess Medical Center Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040247563A1 (en) 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
AU2002224851A1 (en) 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
JP2004520033A (ja) 2001-01-15 2004-07-08 イ・デ・エム・イミュノ−デジネ・モレキュル 分化拘束された成熟樹状細胞の調製用補助組成物
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
EP1270732A1 (en) 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
WO2003010301A1 (en) 2001-07-25 2003-02-06 I.D.M. Immuno-Designed Molecules New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DK1437358T3 (da) 2001-08-16 2007-02-05 Daiichi Asubio Pharma Co Ltd Hidtil ukendt glycolipid og medikament til autoimmune sygdomme indeholdende dette som det aktive stof
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
EP1572228A4 (en) 2002-09-19 2009-03-04 Centocor Inc METHOD FOR THE INTRODUCTION OF THE TREATMENT OF DENDRITIC CELLS AND ITS USES
WO2004026318A1 (ja) 2002-09-20 2004-04-01 Kirin Beer Kabushiki Kaisha α-グリコシルセラミドを有効成分とするC型肝炎ウイルス抑制剤
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
AU2004277376B2 (en) 2003-07-18 2011-06-02 Eastern Virginia Medical School Apparatus for generating electrical pulses and methods of using the same
CN1882603A (zh) 2003-11-25 2006-12-20 阿哥斯医疗公司 mRNA转染的抗原呈递细胞
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5020935B2 (ja) * 2005-04-08 2012-09-05 アルゴス セラピューティクス,インコーポレイティド 樹状細胞組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008207A1 (en) * 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blaeser, F. et al. Clinical Immunology, vol. 117 (2005), pp. 231- 237 *

Also Published As

Publication number Publication date
JP5425618B2 (ja) 2014-02-26
JP2009533025A (ja) 2009-09-17
EP2003969A4 (en) 2009-05-13
CN101460054A (zh) 2009-06-17
CN101460054B (zh) 2014-03-12
KR20090006078A (ko) 2009-01-14
EP2003969A2 (en) 2008-12-24
ATE510451T1 (de) 2011-06-15
WO2007117682A2 (en) 2007-10-18
US20120269832A1 (en) 2012-10-25
CA2648675C (en) 2015-03-10
US20170096639A1 (en) 2017-04-06
US10184108B2 (en) 2019-01-22
US9523077B2 (en) 2016-12-20
DK2003969T3 (da) 2011-09-12
AU2007235227A1 (en) 2007-10-18
US20140017788A1 (en) 2014-01-16
WO2007117682A3 (en) 2008-10-16
KR101425686B1 (ko) 2014-08-01
US8513008B2 (en) 2013-08-20
CA2648675A1 (en) 2007-10-18
US20070082400A1 (en) 2007-04-12
EP2003969B1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
AU2007235227B2 (en) Mature dendritic cell compositions and methods for culturing same
US11248209B2 (en) Mature dendritic cell compositions and methods for culturing same
AU2015218865B2 (en) TSCM cells and methods for use
WO2008055354A1 (en) Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
HK1105997B (en) Mature dendritic cell compositions and methods for culturing same
HK1144588A (en) Mature dendritic cell compositions and methods for culturing same
HK1144588B (en) Mature dendritic cell compositions and methods for culturing same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARGOS THERAPEUTICS, INC.

Free format text: FORMER OWNER WAS: KYOWA HAKKO KIRIN CO., LTD.; ARGOS THERAPEUTICS, INC.

PC Assignment registered

Owner name: COIMMUNE, INC.

Free format text: FORMER OWNER(S): ARGOS THERAPEUTICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired